{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001979","form_type":"8-K","ticker":"SLSN","cik":"0000883107","company_name":"SOLESENCE, INC.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.376587+00:00","generated_at":"2026-06-17T11:34:29.048165+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nanophase reports record FY2022 revenue $37.3M (+27% YoY) but net loss of $2.6M","bullets":["FY2022 revenue $37.3M, up 27% YoY; Q4 revenue $8.3M, up 12% YoY.","Net loss $2.6M ($0.05/sh) vs net income $2.3M ($0.05/sh) in 2021.","Solésence revenue $23.1M (+27%); Personal Care Ingredients $11.1M (+44%); Advanced Materials $3.1M (-14%).","Atypical expenses $1.6M: $0.7M cyber theft loss, $0.4M litigation legal fees, $0.3M bad debt.","Received US patent allowance for Kleair skin health tech; named No.2 in Fast Company Beauty innovation list."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001979","json":"https://secwatch.observer/filing/0001171843-23-001979.json","markdown":"https://secwatch.observer/filing/0001171843-23-001979.md","text":"https://secwatch.observer/filing/0001171843-23-001979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/883107/000117184323001979/0001171843-23-001979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883107/000117184323001979/f8k_032923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T11:34:29.048165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}